Table 1. Comparison of bridge trial and other smaller retrospective studies that used cangrelor as bridging therapy for DAPT.
| Study/author | Study type | Subjects (in n) | Cangrelor dose (in mcg/kg/min) | Level of platelet reactivity (in PRUs) | Major bleeding in cangrelor group (as a fraction of the total) | Ischemic or thrombotic events (as a fraction of the total) |
|---|---|---|---|---|---|---|
| BRIDGE (8) | Prospective, multicenter RCT | 210 | 0.75 | <240 PRU | 12 of 102 | 3 of 106 |
| Kairouz et al. (29) | Prospective | 27 | 0.75 | NA | 2 of 27 | NR |
| Bowman et al. (26) | Retrospective, case series | 11 | 0.5–2 | <208 PRU | 3 of 11 | None |
| Washam et al. (30) | Retrospective, case series | 5 | 0.75 | NA | 2 of 5 | None |
| Stern et al. (31) | Retrospective, case series | 22 | 0.75 | NA | 10 of 22 | NR |
DAPT, dual antiplatelet therapy; RCT, randomized controlled trial; PRU, P2Y12 reaction unit; NR, not reported; NA, not applicable.